Role of Inflammatory Markers in Sepsis

Role of Inflammatory Markers Measured Using Flow Cytometry in the Diagnosis and Prognosis of Sepsis in Surgical Cancer Patients

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06111963

Enrollment

Registered

2023-11-01

Start date

2023-11-01

Completion date

2025-01-25

Last updated

2025-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diagnostic

Brief summary

A diagnostic and prognostic study, in which the expression of CD64 in activated neutrophils and CD64 and IL17A regulatory T cells in patients with sepsis will be evaluated as a probable marker for sepsis as a primary objective

Interventions

DIAGNOSTIC_TESTSerology tests

CD4, CD25, IL17

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Cancer patients admitted to the surgical ICU following cancer related surgeries and diagnosed with sepsis

Exclusion criteria

* Refusal of patient or patient guardian to participate. * Intraoperative massive blood loss and massive blood transfusion * Patients with impaired preoperative kidney or liver function tests

Design outcomes

Primary

Measure	Time frame	Description
To evaluate the expression CD4	7 days	Serology
To evaluate the expression CD25	7 days	Serology
To evaluate the expression IL17	7 days	Serology

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026